menu
    • menu
    [{"orgOrder":0,"company":"Bayer AG","sponsor":"Corporaci\u00f3n Bonima","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cephalexin","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Corporaci\u00f3n Bonima","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Corporaci\u00f3n Bonima"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Corporaci\u00f3n Bonima","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cephalexin","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bayer AG \/ Corporaci\u00f3n Bonima","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Corporaci\u00f3n Bonima"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Corporaci\u00f3n Bonima","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cephalexin","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bayer AG \/ Corporaci\u00f3n Bonima","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Corporaci\u00f3n Bonima"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Cephalexin","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Cephalexin","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Cephalexin","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Cephalexin","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Ottawa Hospital Research Institute","sponsor":"The Ottawa Hospital Academic Medical Association | Canadian Association of Emergency Physicians","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cephalexin","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Ottawa Hospital Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ottawa Hospital Research Institute \/ The Ottawa Hospital Academic Medical Association | Canadian Association of Emergency Physicians","highestDevelopmentStatusID":"11","companyTruncated":"Ottawa Hospital Research Institute \/ The Ottawa Hospital Academic Medical Association | Canadian Association of Emergency Physicians"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Investigacion Farmacologica y Biofarmaceutica","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Cephalexin","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Investigacion Farmacologica y Biofarmaceutica","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Investigacion Farmacologica y Biofarmaceutica"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Investigacion Farmacologica y Biofarmaceutica","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Cephalexin","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Investigacion Farmacologica y Biofarmaceutica","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Investigacion Farmacologica y Biofarmaceutica"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Investigacion Farmacologica y Biofarmaceutica","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Cephalexin","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Investigacion Farmacologica y Biofarmaceutica","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Investigacion Farmacologica y Biofarmaceutica"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Investigacion Farmacologica y Biofarmaceutica","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Cephalexin","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Investigacion Farmacologica y Biofarmaceutica","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Investigacion Farmacologica y Biofarmaceutica"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Investigacion Farmacologica y Biofarmaceutica","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Cephalexin","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Investigacion Farmacologica y Biofarmaceutica","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Investigacion Farmacologica y Biofarmaceutica"},{"orgOrder":0,"company":"Western Sydney Local Health District","sponsor":"Centre Of Research Excellence in Tuberculosis Control","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cephalexin","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Western Sydney Local Health District","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Western Sydney Local Health District \/ Centre Of Research Excellence in Tuberculosis Control","highestDevelopmentStatusID":"8","companyTruncated":"Western Sydney Local Health District \/ Centre Of Research Excellence in Tuberculosis Control"}]

    Find Clinical Drug Pipeline Developments & Deals for Ibilex

    Menu

    Ibilex

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Western Sydney Local Health District

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Western Sydney Local Health District

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cephalexin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Centre Of Research Excellence in Tuberculosis Control

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The BLAST- 1 Trial - Cephalexin+Amoxicillin-clavulanate for Tuberculosis

                            Details : Cephalexin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Tuberculosis, Pulmonary.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 23, 2022

                            Lead Product(s) : Cephalexin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Centre Of Research Excellence in Tuberculosis Control

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ottawa Hospital Research Institute

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Ottawa Hospital Research Institute

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cephalexin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : The Ottawa Hospital Academic Medical Association | Canadian Association of Emergency Physicians

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            High-dose vs. Standard-dose Cephalexin for Cellulitis

                            Details : Cephalexin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cellulitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 15, 2020

                            Lead Product(s) : Cephalexin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : The Ottawa Hospital Academic Medical Association | Canadian Association of Emergency Physicians

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Rambam Health Care Campus

                            Israel arrow
                            OTS 2025
                            Not Confirmed

                            Rambam Health Care Campus

                            Israel arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cephalexin

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effect of Prophylactic Antibiotics on Surgical Site Infection Lower Limb Skin Excisions

                            Details : Cephalexin is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 29, 2017

                            Lead Product(s) : Cephalexin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Eli Lilly

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cephalexin

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Investigacion Farmacologica y Biofarmaceutica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Cephalexin Liquid in Healthy Participants

                            Details : Cephalexin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 07, 2015

                            Lead Product(s) : Cephalexin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Investigacion Farmacologica y Biofarmaceutica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Eli Lilly

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cephalexin

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Investigacion Farmacologica y Biofarmaceutica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Cephalexin Capsules in Healthy Participants

                            Details : Cephalexin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 25, 2014

                            Lead Product(s) : Cephalexin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Investigacion Farmacologica y Biofarmaceutica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Eli Lilly

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cephalexin

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Investigacion Farmacologica y Biofarmaceutica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Cephalexin Suspension in Healthy Participants

                            Details : Cephalexin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 25, 2014

                            Lead Product(s) : Cephalexin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Investigacion Farmacologica y Biofarmaceutica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Eli Lilly

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cephalexin

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Investigacion Farmacologica y Biofarmaceutica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Cephalexin Liquid for Pediatrics in Healthy Adults Participants

                            Details : Cephalexin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 25, 2014

                            Lead Product(s) : Cephalexin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Investigacion Farmacologica y Biofarmaceutica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Eli Lilly

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cephalexin

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Investigacion Farmacologica y Biofarmaceutica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Cephalexin in Healthy Participants

                            Details : Cephalexin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 01, 2014

                            Lead Product(s) : Cephalexin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Investigacion Farmacologica y Biofarmaceutica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            GSK

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cephalexin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Cephalexin Suspension 125

                            Details : Cephalexin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Respiratory Tract Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 14, 2013

                            Lead Product(s) : Cephalexin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            GSK

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cephalexin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Cephalexin Suspension 250

                            Details : Cephalexin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Respiratory Tract Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 14, 2013

                            Lead Product(s) : Cephalexin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth